Larynx News and Research

RSS

Boehringer Ingelheim initiates two afatinib phase III trials in head and neck cancer

Boehringer Ingelheim announced today the initiation of two phase III clinical trials, LUX-Head & Neck 1 and LUX-Head & Neck 2. These trials evaluate afatinib in patients with metastatic and recurrent head and neck cancer, and in patients with locally advanced disease, respectively.

27 Jan 2012

miR-375 can predict life threatening head and neck cancers

Researchers at Albert Einstein College of Medicine of Yeshiva University and Montefiore Medical Center, the University Hospital for Einstein, have found a biomarker in head and neck cancers that can predict whether a patient's tumor will be life threatening.

24 Jan 2012

ViroPharma's NDS for Cinryze receives Health Canada's Priority Review status

ViroPharma Incorporated today announced that Health Canada has granted the company Priority Review status for its New Drug Submission (NDS) for Cinryze (C1 inhibitor [human]).

13 Jan 2012

FDA approves CSL Behring's Berinert for treatment of HAE attacks

CSL Behring today announced that the U.S. Food and Drug Administration (FDA) has approved a label expansion for self-administration of Berinert, C1 Esterase Inhibitor (Human), a pasteurized, nanofiltered therapy indicated for the treatment of acute attacks of hereditary angioedema (HAE), a rare and potentially fatal genetic disorder.

4 Jan 2012

New procedure helps reconstruct cricoid cartilage in a cancer patient

When Sherry Wittenberg was diagnosed with a rare cancer in the cricoid cartilage of her larynx, doctors told her the only way to treat the condition was to remove her voice box. The operation would leave her unable to speak normally and would require her to breathe through a hole in her neck for the rest of her life.

17 Dec 2011

Positive results from Oncolytics REOLYSIN combination Phase 2 clinical trial for head and neck cancers

Oncolytics Biotech Inc. today announced that positive results from a Phase 2 clinical trial (REO 015) using intravenous administration of REOLYSIN in combination with paclitaxel and carboplatin in patients with advanced head and neck cancers will be presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.

14 Nov 2011

ASHG to honor U of U geneticist with William Allan Award

As a teenager just moved to Iowa from war-ravaged Germany in 1951, John M. Opitz, M.D., wanted to study developmental biology, but his "very Prussian" mother insisted he go to medical school instead.

12 Oct 2011

Study finds high prevalence of cigar use among young adults and minorities

A new study in October issue of the American Journal of Public Health measures brand usage trends and the prevalence of cigar use among specific populations.

20 Sep 2011

ViroPharma initiates Cinryze Phase 2 subcutaneous trial in patients with HAE

ViroPharma Incorporated and Halozyme Therapeutics announced today that ViroPharma has initiated an open-label, multi-dose Phase 2 study to evaluate the safety, and pharmacokinetics and pharmacodynamics of subcutaneous administration of Cinryze in combination with Halozyme's Enhanze technology, a proprietary drug delivery platform using Halozyme's recombinant human hyaluronidase enzyme, in subjects with hereditary angioedema.

14 Sep 2011

Henry Ford study identifies 23 microRNAs for laryngeal cancer

A Henry Ford Hospital study has identified 23 microRNAs for laryngeal cancer, a discovery that could yield new insight into what causes certain cells to grow and become cancerous tumors in the voice box.

14 Sep 2011

IRIDEX introduces new XP Module for IQ 532 ENT laser system

IRIDEX Corporation announced the introduction of its new XP Module - a high power factory installed option for the IRIDEX IQ 532 green laser system.

31 Aug 2011

Astellas seeks regulatory approval for mirabegron to treat overactive bladder in the U.S., Europe

Astellas Pharma Inc. today announced the submission of a New Drug Application and Market Authorisation Application for mirabegron to the U.S. Food and Drug Administration and the European Medicines Agency.

29 Aug 2011

CIRM approves stem cell research planning grants for five UC Davis teams

The California Institute for Regenerative Medicine (CIRM), the state stem cell agency, today approved research planning grants for five UC Davis Health System teams that are working to develop human clinical trials to treat illnesses such as Huntington's disease, vascular disease, osteoporosis, HIV/AIDS and airway disease in children.

29 Aug 2011

Shire receives FDA marketing approval for FIRAZYR to treat acute attacks of HAE

Shire plc, the global specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for FIRAZYR for treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.

26 Aug 2011

Researchers develop epidermal electronic system

Through a combination of careful theoretical modeling and precise micro-manufacturing, a team of engineers and scientists has developed a new type of ultra-thin, self-adhesive electronics device that can effectively measure data about the human heart, brain waves and muscle activity - all without the use of bulky equipment, conductive fluids, or glues.

12 Aug 2011

Alcohol, tobacco use increase risk of upper aero-digestive tract cancers

Upper aero-digestive tract cancers (UADT), especially those of the oral cavity, pharynx, and larynx, are often referred to as alcohol-related cancers as it has been shown repeatedly that heavy drinkers, in particular, are at increased risk.

3 Aug 2011

Studies reveal new set of mutations linked with head and neck cancer

Powerful new technologies that zoom in on the connections between human genes and diseases have illuminated the landscape of cancer, singling out changes in tumor DNA that drive the development of certain types of malignancies such as melanoma or ovarian cancer.

29 Jul 2011

UK’s first larynx transplant

In a first, UK will get its voicebox or larynx transplant in less than a year after the Royal College of Surgeons gave its seal of approval for trials to take place. A report by the college said the pioneering procedure could help people who had cancer of the larynx to speak and breathe normally again.

19 Jun 2011

ViroPharma receives European Centralized Marketing Authorization for Cinryze for treatment of HAE

ViroPharma Incorporated today announced that the European Commission has granted ViroPharma Centralized Marketing Authorization for Cinryze (C1 inhibitor [human]) in adults and adolescents with hereditary angioedema (HAE) for routine prevention, pre-procedure prevention and acute treatment of angioedema attacks.

16 Jun 2011

Cinryze data on hereditary angioedema presented at EAACI 2011

ViroPharma Incorporated today announced that data relating to Cinryze from nine accepted abstracts were presented as poster presentations at the 30th Congress of the European Academy of Allergy and Clinical Immunology (EAACI), June 11 through 15, in Istanbul, Turkey.

14 Jun 2011